In various cancer models, targeted therapy using monoclonal antibodies efficiently prevents EGFR ligand binding, and receptor dimerization promotes EGFR phosphorylation and internalization, which ultimately reduces cell proliferation 4. The gene discussed is EGFR; the disease is cancer.